IDBS said this week that the Segal Cancer Center at the Jewish General Hospital and the Quebec-Clinical Research Organization Consortium (Q-CROC) have selected its Translational Science Solution to mange cancer-related omics data for a personalized medicine program.
IDBS said that scientists conducting serial biopsy trials — initially with breast cancer, melanoma, and colorectal cancer patients — at these centers will use its solution to capture molecular signatures for omics data profiled from patients’ metastatic cancer tumors, which will help them choose more appropriate treatments for patients.
The software will also support a new program across Quebec that prospectively collects information on primary tumors with the aim of building a vast biobank and accompanying database that will help researchers easily identify and access patient sub-groups and will support patient stratification in drug development. Researchers will follow patients throughout their cancer trajectory including at the time of tumor relapses when the patients might participate in the Q-CROC serial biopsy trials.
Gerald Batist, director of the Segal Cancer Center and scientific director of Q-CROC, said in a statement that the centers selected IDBS platform because its data management capabilities adequately met their need for software "to capture, integrate, and analyze not only our own data" but also data from public databases and other sources.
"We anticipate it being a key tool as we join forces across the pharma industry," he added.
The financial details of the agreement were not disclosed.